FDA proposes ban on bulk compounding of semaglutide and tirzepatide
The FDA has proposed excluding weight-loss drugs, such as Ozempic/Wegovy and Zepbound from a key compounding list, potentially limiting large-scale production by outsourcing facilities. Today’s News Updated on May 13, 2026 at 8:00 a.m. PST ...